Aeglea BioTherapeutics, Inc. announced that effective May 16, 2023, the employment Of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of the company was terminated.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.3 USD | +3.88% | +0.73% | +52.97% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.97% | 1.29B | |
+7.47% | 114B | |
+8.65% | 104B | |
-0.35% | 22.57B | |
-12.01% | 22.5B | |
-10.53% | 17.95B | |
-41.90% | 16.48B | |
-14.90% | 15.82B | |
+2.26% | 13.55B | |
+28.05% | 10.99B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer